

WHAT WE CLAIM IS:

1. A solid pharmaceutical composition for treating a cyclooxygenase-2
5 dependent disorder or condition comprising between about 200 and about 400 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, wherein the residual moisture levels of said composition is between about 1.5% and about 5%.
2. The solid pharmaceutical composition of claim 1 comprising about 200
10 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, wherein the residual moisture level of said composition is between about 2% and about 5%.
3. The solid pharmaceutical composition of claim 2 wherein the residual
moisture level of said composition is between about 2.1% and about 4.5%.
- 15 4. The solid pharmaceutical composition of claim 3, wherein the residual moisture level of said composition is about 3.5%.
5. The solid pharmaceutical composition of claim 1 comprising about 400
20 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, wherein the residual moisture level of said composition is between about 1.5% and about 4%.
6. The solid pharmaceutical composition of claim 5 comprising about 400
mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, wherein the residual
25 moisture level of said composition is between about 1.7% and about 3.5%.
7. The solid pharmaceutical composition of claim 6, wherein the residual
moisture level of said composition is about 2.5%.

8. The solid pharmaceutical composition of claim 3, wherein said composition is a tablet.

9. The solid pharmaceutical composition of claim 4, wherein said
5 composition is a tablet.

10. The solid pharmaceutical composition of claim 6, wherein said composition is a tablet.

10 11. The solid pharmaceutical composition of claim 7, wherein said composition is a tablet.

12. A method for stabilizing 5-methyl-2-(2'-chloro-6'-
fluoroanilino)phenylacetic acid in a solid pharmaceutical composition, comprising
15 producing a solid pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-
fluoroanilino)phenylacetic acid wherein said composition has a residual moisture level
between about 1.5% and about 5%.

13. The method of claim 12, wherein said solid pharmaceutical composition
20 comprises about 200 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
wherein the residual moisture level of said composition is between about 2% and about
5%.

14. The method of claim 13 wherein said solid pharmaceutical composition
25 comprises about 200 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
wherein the residual moisture level of said composition is between about 2.1% and about
4.5%.

15. The method of claim 14 wherein said solid pharmaceutical composition
30 comprises about 200 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and

wherein the residual moisture level of said composition is between about 3% and about 4%.

16. The method of claim 15 wherein said solid pharmaceutical composition
5 comprises about 200 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
wherein the residual moisture level of said composition is about 3.5%.

17. The method of claim 12, wherein said solid pharmaceutical composition
comprises about 400 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
10 wherein the residual moisture level of said composition is between about 1.5% and about
4%.

18. The method of claim 17 wherein said solid pharmaceutical composition
comprises about 400 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
15 wherein the residual moisture level of said composition is between about 1.7% and about
3.5%.

19. The method of claim 18 wherein said solid pharmaceutical composition
comprises about 400 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
20 wherein the residual moisture level of said composition is between about 2% and about
3%.

20. The method of claim 19 wherein said solid pharmaceutical composition
comprises about 400 mg of 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and
25 wherein the residual moisture level of said composition is about 2.5%.

21. A dried granulation comprising 5-methyl-2-(2'-chloro-6'-
fluoroanilino)phenylacetic acid, microcrystalline cellulose, lactose monohydrate,
croscarmellose sodium, wherein the residual moisture level of said granulation is between
30 about 2.5% and about 4.5%.

22. The dried granulation of claim 21, wherein the residual moisture level of said granulation is between about 3% and about 3.75%.

5 23. The dried granulation of claim 22, wherein the residual moisture level of said granulation is about 3.5%.

24. A dried granulation comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, croscarmellose sodium, povidone, wherein the residual
10 moisture level of said granulation is between about 1.5% and about 4%.

25. The dried granulation of claim 24, wherein the residual moisture level of said granulation is between about 1.7% and about 3.5%.

15 26. The dried granulation of claim 25, wherein the residual moisture level of said granulation is between about 2% and about 3%.

27. The dried granulation of claim 26, wherein the residual moisture level of said granulation is about 2.5%.

20 28. A solid pharmaceutical composition comprising the dried granulation of claim 21.

29. A solid pharmaceutical composition comprising the dried granulation of
25 claim 22.

30. A solid pharmaceutical composition comprising the dried granulation of claim 25.

31. A solid pharmaceutical composition comprising the dried granulation of claim 26.